骨癌藥物市場：依藥物類型、適應症、配銷通路和地區分類

預計2023年骨癌藥物的全球市場規模為12.864億美元，預計在預測期內（2023-2030年）年複合成長率為5.2%。

骨癌藥物全球市場佔有率（%）（以藥物類型），2023年

骨癌是指發生在骨骼中的各種惡性。當癌細胞擴散到骨骼時，它們會損害正常骨組織。骨癌的類型取決於首先出現該疾病的細胞和組織的類型。原發性骨惡性是在骨頭本身內發生的腫瘤。許多始於身體器官或其他組織的癌症可以擴散到骨骼以及身體的其他部位。這些生長稱為轉移性或繼發性骨惡性。大多數轉移（轉移）到骨骼的腫瘤起源於乳房、前列腺或肺部。在骨癌中，異常骨細胞生長失控並破壞正常骨組織。它可能從骨骼開始或擴散到身體的其他部位（稱為轉移）。骨癌很少見。大多數骨腫瘤是良性的，這意味著它們不會癌變或擴散到身體的其他部位。然而，它會削弱骨骼並導致骨折。良性骨腫瘤有幾種常見類型：骨軟骨瘤是最常見的。它在20歲以下的人群中更為常見。鉅細胞瘤見於腿部。在極少數情況下，它可能會癌變。骨樣骨瘤通常發生在長骨中，通常發生在 20 歲出頭的人身上。骨母細胞瘤是一種罕見的脊椎和長骨腫瘤，主要發生在年輕人身上。軟骨瘤通常發生在手和腳的骨頭。在許多情況下沒有任何症狀。這是最常見的手部腫瘤類型。因此，骨癌患病的增加預計將在預測期內推動全球骨癌治療市場的成長。

市場動態

產品數量的增加和政府法規機構核准預計將推動預測期內全球骨癌治療市場的成長。例如，2021年2月，美國食品藥物管理局（FDA）授予骨靶向放射性藥物釤-153-DOTMP（CycloSam）罕見兒科疾病認定，作為骨癌。。此核技術使用低密度釤153（可減少銪污染）和DOTMP（一種旨在防止高骨骼代謝目標部位脫靶遷移的螯合劑）。

本研究的主要特點

• 本報告對全球骨癌治療市場進行了詳細分析，並提出了以2022年為基準年的預測期（2023-2030）的市場規模和複合年度（年複合成長率）。
• 它還闡明了各個細分市場的潛在收入機會，並解釋了該市場有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
• 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球骨癌藥物市場的主要企業。
• 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場經營團隊和行銷策略做出明智的資訊。
• 全球骨癌藥物市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 相關人員可以透過用於分析全球骨癌藥物市場的各種策略矩陣來促進他們的決策。

目錄

第1章 調查目的和假設

• 這項研究的目的
• 假設
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章 市場動態、法規及趨勢分析

• 市場動態
• 促進因素
• 抑制因素
• 機會
• 市場趨勢
• 法規場景
• 新產品上市/核准
• 合併、收購和合作場景
• PEST分析
• 波特的分析

第4章 全球骨癌治療藥物市場－新型冠狀病毒感染疾病（COVID-19）影響分析

• 經濟影響
• 新型冠狀病毒感染疾病（COVID-19）的流行病學
• 對需求和供給的影響

第5章 全球骨癌藥物市場，依藥物類型，2023-2030

• 抗代謝物
• 蒽環類藥物
• 抗生素
• 其他（RANK配體抑制劑等）

第6章 2023-2030年全球骨癌藥物市場（依疾病適應症）

• 多發性骨髓瘤
• 骨癌
• 軟骨肉瘤
• 尤文氏肉瘤

第7章 全球骨癌藥物市場，依配銷通路分類，2023-2030 年

• 醫院藥房
• 零售藥房
• 網路藥房

第8章 2023-2030年全球骨癌藥物市場（按地區）

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東
• 非洲

第9章 競爭形勢

• 公司簡介
  • Advaxis, Inc.
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck &Co
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical

第10章 章

• 參考
• 調查方法

Global bone cancer drugs market is estimated to be valued at US$ 1,286.4 Mn in 2023, and is expected to exhibit a CAGR of 5.2% during the forecast period (2023-2030).

Global Bone Cancer Drugs Market Share (%), By Drug Type, 2023

The term "bone cancer" refers to a variety of malignancies that in the bones. Normal bone tissues may suffer damage, if the cancer cells spread into a bone. The type of bone cancer depends on the cell and tissue types where the disease first manifests itself. Primary bone malignancies are tumors that originate inside the bone itself. Many cancers that start in the body organs or other tissues can spread to the bones in addition to other body parts. These growths are referred to as metastatic or secondary bone malignancies. Most tumors that metastasis (spread) to the bones are from the breast, prostate, and lung. In bone cancer, abnormal cells in bone grow out of control and destroys the normal bone tissue. It can start in bone or spread to other parts of body (called metastasis). Bone cancer is rare. Most bone tumors are benign, and thus, these are not cancerous and will not spread to other areas of your body. However, these can weaken bones and lead to fractures or other problems. There are a few common types of benign bone tumors: Osteochondroma is the most common. It is common in people under the age of 20. A giant cell tumor is present in leg. In rare cases, these can also be cancerous. Osteoid osteomas often occur in long bones, usually in the early 20s. Osteoblastoma is a rare tumor that grows in the spine and long bones, and occurs primarily in young adults. Enchondromas usually appear in the bones of hands and feet. Often there are no symptoms. It is the most common type of hand tumor. Thus, increasing prevalence of bone cancer is expected to drive growth of the global bone cancer drugs market over the forecast period.

Market Dynamics

Increasing products and approvals by government regulatory bodies is expected to drive growth of the global bone cancer drugs market over the forecast period. For instance, in February 2021, the U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to the bone-targeting radiopharmaceutical samarium-153-DOTMP (CycloSam) for use as a potential therapeutic option for patients with osteosarcoma. The nuclear technology uses low specific activity samarium-153 thatreduces europium contamination, and DOTMP, a chelator designed to prevent off-target migration and at target sites with high bone turnover.

Key features of the study:

• This report provides an in-depth analysis of the global bone cancer drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bone cancer drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co., Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd and Teva Pharmaceutical
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global bone cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drugs market

Detailed Segmentation:

• Global Bone Cancer Drugs Market, By Drug Type:
  • Antimetabolites
  • Anthracyclines
  • Antibiotics
  • Others (RANK ligand inhibitors, etc.)
• Global Bone Cancer Drugs Market, By Disease Indication:
  • Multiple Myeloma
  • Osteosarcoma
  • Chondrosarcoma
  • Ewing's Sarcoma
• Global Bone Cancer Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Bone Cancer Drugs Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Advaxis, Inc.
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck & Co
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Market Trends
• Regulatory Scenario
• New Product Launches/Approvals
• Merger, Acquisition and Collaboration Scenario
• PEST Analysis
• PORTER's Analysis

4. Global Bone Cancer Drugs Market - COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Bone Cancer Drugs Market, By Drug Type, 2023- 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2023-2030
  • Segment Trends
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Anthracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Others (RANK ligand inhibitors, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

6. Global Bone Cancer Drugs Market, By Disease Indication, 2023 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Multiple Myeloma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
• Osteosarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)
• Chondrosarcoma
  • Introduction
• Ewing's Sarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Bone Cancer Drugs Market, By Distribution Channel, 2023 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2023-2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023 - 2030, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2023- 2030, (US$ Mn)

8. Global Bone Cancer Drugs Market, By Region, 2023 - 2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region, 2023-2030
  • Segment Trends
• North America
  • Market Size and Forecast,and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • U.S.
  • Canada
• Europe
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2023-2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023 -2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2023-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Company Profiles
  • Advaxis, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Cellectar Biosciences, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • OPKO Health, Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Pfizer Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Amgen Inc.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Novartis AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Eli Lilly and Company
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Debiopharm Group
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Merck & Co
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Bayer AG
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Bristol-Myers Squibb Company
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Takeda Pharmaceutical
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • F. Hoffmann-La Roche Ltd.
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Teva Pharmaceutical
• Company Overview
• Product Portfolio
• Key Highlights
• Financial Overview
• Strategies
  • Analyst Views

10. Section

• References
• Research Methodology
• About us and Sales Contact